Voyager Therapeutics’ Innovative CNS Pipeline and Promising Alzheimer’s Developments Justify Buy Rating
H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating today. Patrick ...
Voyager Therapeutics (VYGR) Receives a Buy from Truist Financial
In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...